Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ddr.21862 http://scihub22266oqcxt.onion/10.1002/ddr.21862 34323298!8426670!34323298     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Dev+Res 2021 ; 82 (7): 880-882 Nephropedia Template TP {{tp|p=34323298|t=2021. Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics |pdf=|usr=}}{{34323298}} gab.com Text Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics JO: Drug Dev Res http://www.kidney.de/pget.php?&tw=1&pmid=34323298 #FOAvip COVID-19's second wave had a significant impact on India, on May 7, 2021, the largest daily recorded case count was a little more than 4 million, and it has since fallen. Although the number of new cases reported has dropped, during the third week of May 2021, India accounted for about 45% of new cases identified globally and around 34% of deaths. As India maintains its present level of stability, a new urgent threat has emerged in the form of coronavirus-associated mucormycosis. Mucormycosis, an acute and deadly fungal infection caused by Mucorales-related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified, and treated. Mucormycosis, sometimes referred to as the "black fungus," has increased more rapidly in India during the second wave of COVID-19 than during the first wave, with at least 14,872 cases as of May 28, 2021. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits. Twit Text FOAVip Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics ????Drug Dev Res http://www.kidney.de/pget.php?&tw=1&pmid=34323298 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34323298 #FOAvip English Wikipedia <ref>{{Cite pmid|34323298}}</ref> Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics #MMPMID34323298 Gupta G; S R; Singh Y; Thangavelu L; Singh SK; Dureja H; Chellappan DK; Dua K Drug Dev Res 2021[Nov]; 82 (7): 880-882 PMID34323298show ga COVID-19's second wave had a significant impact on India, on May 7, 2021, the largest daily recorded case count was a little more than 4 million, and it has since fallen. Although the number of new cases reported has dropped, during the third week of May 2021, India accounted for about 45% of new cases identified globally and around 34% of deaths. As India maintains its present level of stability, a new urgent threat has emerged in the form of coronavirus-associated mucormycosis. Mucormycosis, an acute and deadly fungal infection caused by Mucorales-related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified, and treated. Mucormycosis, sometimes referred to as the "black fungus," has increased more rapidly in India during the second wave of COVID-19 than during the first wave, with at least 14,872 cases as of May 28, 2021. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits. |*Prescription Drug Misuse[MESH] |Anti-Bacterial Agents/*adverse effects/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*complications[MESH] |Emergency Medical Services[MESH] |Glucocorticoids/adverse effects/therapeutic use[MESH] |Humans[MESH] |India[MESH] |Mucormycosis/*epidemiology/*etiology[MESH] |Pandemics[MESH] |Prognosis[MESH]Emerging cases of mucormycosis under COVID-19 pandemic in India: Misus(epmc).pdf DeepDyve Pubget Overpricing